Ignite Creation Date:
2024-05-06 @ 3:03 PM
Last Modification Date:
2024-10-26 @ 1:41 PM
Study NCT ID:
NCT04501679
Status:
COMPLETED
Last Update Posted:
2024-07-10
First Post:
2020-07-30
Brief Title:
A Study to Assess the Efficacy and Safety of Nemolizumab CD14152 in Participants With Prurigo Nodularis PN
Sponsor:
Galderma RD
Organization:
Galderma RD
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab CD14152 in Subjects With Prurigo Nodularis
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective was to assess the efficacy of nemolizumab CD14152 compared to placebo in participants greater than or equal to 18 years of age with prurigo nodularis PN after a 16-week treatment period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2019-004789-17 | EUDRACT_NUMBER | None | None |